Aridis To Discuss Topline Data From Phase 3 S. aureus Study On Call On Jan. 25

Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, will host a conference call and audio-only webcast on Wednesday, January 25, at 4:15 p.m. ET to provide a business and pipeline update, including a discussion of topline data from the Company’s Phase 3 study of AR-301 in adjunctive treatment of S. aureus ventilator associated pneumonia (VAP). The Company expects to publish topline data from AR-301 on January 25, prior to the call. A question-and-answer session will follow management’s prepared remarks.

Event:	Aridis Pharmaceuticals Corporate Update Conference Call
Date:	Wednesday, January 25, 2023
Time:	4:15 p.m. Eastern Time
Live Call:	+1-877-407-9208 (U.S. Toll-Free) or +1-201-493-6784 (International)
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1588876&tp_key=33c334b81c

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until February 8, 2023 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13735220.

https://finance.yahoo.com/news/aridis-pharmaceuticals-discuss-topline-data-133000953.html

Altamira Covid Trial Misses Primary Endpoint

 

• Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal symptom primary endpoint over saline nasal spray comparator

• NASAR main trial phase completed; full read-out expected in Q2 2023

• Top line data from COVAMID trial in acute COVID-19 show trend for more pronounced reduction in nasal viral load and symptoms than no treatment, but primary endpoint not met 

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR) and acute COVID-19. Bentrio nasal spray is intended to help protect against airborne allergens and viruses.

https://finance.yahoo.com/news/altamira-therapeutics-provides-clinical-trials-131700567.html

Nemaura Medical's Program Shows Weight Loss In 100% Of Participants

 

• Nemaura Medical Inc (NASDAQ: NMRD) has announced initial results from patient studies of its metabolic health program Miboko with the National Health Service (NHS) in the U.K.

• The initial pilot program recruited 30 individuals classified as obese according to their BMI.

• The first cohort of 10 patients enrolled in the program for over 12 weeks.

• Results from this cohort indicate that these individuals achieved an average weight loss of 3.7 pounds and an average BMI improvement of 0.6 after 10 weeks, with 100% of participants achieving some weight improvement.

• Participants' feedback shows that the body-worn sensor's use led to greater engagement and an element of gamification that is anticipated to lead to sustained use and encourage incremental dietary and lifestyle changes through a combination of personalized data and targeted education modules.

• Participants expressed their willingness to continue with the program.

• The Miboko program is the first to integrate a daily-wear non-invasive glucose sensor with a lifestyle app, which includes a recording of food and drink, educational content, and an analytics platform.

https://finance.yahoo.com/news/nemaura-medicals-program-shows-weight-172734044.html

Cosmos Health Announces Stock Buyback

 Cosmos Health, Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $3 million of its common stock.

Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. The timing and total amount of stock repurchases will depend on market conditions, corporate and regulatory requirements, prevailing stock prices and other considerations. The repurchase program expires on January 23, 2024, and may be renewed at the Company's sole discretion.

The repurchase program will be funded using the Company's working capital. As of December 31, 2022, the company had cash, cash equivalents and marketable securities of approximately $21 million (unaudited).

Greg Siokas, Chief Executive Officer of Cosmos Health stated: "This investment reflects our confidence in the Company's operating fundamentals and growth prospects. We believe that this stock repurchase program demonstrates our continued commitment to deliver long-term shareholder value. This plan is a reflection of the confidence we have in our market opportunity and our strategy to invest for long-term growth, which we believe is not reflected in the current market valuation, while creating sustainable value for our stockholders. Cosmos Health is a premier global distributor of over-the-counter pharmaceuticals, as well as producer of its own propriety line of nutraceuticals. Our recently strengthened balance sheet allows us the ability to execute on our multi layered growth strategy which is now underway. We continue to enter into strategic agreements with partners which we expect to lead to revenue growth for many years to come."

https://finance.yahoo.com/news/cosmos-health-announces-stock-buyback-174000304.html

Allogene: First Allogeneic CAR T to Show Safety, Efficacy with Off-the-Shelf Convenience in Multiple Myeloma

 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory (r/r) multiple myeloma (MM) has been published in Nature Medicine.

UNIVERSAL is the first and only allogeneic CAR T study to demonstrate that significant responses can be achieved with a single dose in patients with relapsed/refractory multiple myeloma. These initial study results published in Nature Medicine reinforce our belief that ALLO-715 can induce deep, clinically meaningful responses in patients with an allogeneic cell therapy. AlloCAR T™ product candidates may be able to meaningfully reduce the barriers faced by patients with multiple myeloma when seeking to access cell therapy,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.

https://finance.yahoo.com/news/allogene-therapeutics-announces-publication-nature-133000061.html

Vincerx: FDA Safe to Proceed Letter for IND Application for Small Molecule-Drug Conjugate

 VIP236 is a first-in-class αVβ3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications

Preclinical studies with VIP236 demonstrated promising tumor regression in in vivo cancer models

VIP236 first-in-human study in advanced or metastatic solid tumors anticipated to commence in Q1 2023

https://finance.yahoo.com/news/vincerx-pharma-announces-fda-safe-142900852.html

Baudax: Positive Interim Analysis of Phase 2 Trial in Neuromuscular Blockage

 Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

“We are encouraged by the results of the first interim analysis of the BX1000 Phase II surgery trial,” said Gerri Henwood, Baudax Bio’s President and Chief Executive Officer. “We believe the use of BX1000, combined with our reversal agent, BX3000, could make for precise control of timing under neuromuscular paralysis for surgical patients, which could result in time and cost savings for patients and hospitals alike. We look forward to completing enrollment in the study in Q1 and sharing topline results for the study in April 2023.”

This randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of rocuronium is planned to enroll a total of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia. The primary efficacy endpoint is the proportion of patients meeting criteria for Good or Excellent intubating conditions using a standardized scale. Additionally, the trial is evaluating the safety and tolerability profile of BX1000 and rocuronium in this patient population.

This pre-planned interim analysis evaluated the intubating conditions for each patient after administration of study drug in a blinded fashion. In the 20-patient cohort, 5 patients per group received one of the study medications. All 20 patients were observed to have met the criteria for Good or Excellent intubating conditions at 60 seconds. Nineteen of the subjects were successfully intubated following the assessment at 60 seconds, and the one remaining subject following the assessment at 90 seconds. Study treatments were generally well tolerated with no occurrence of severe or serious adverse events.

https://finance.yahoo.com/news/baudax-bio-announces-positive-outcome-130000794.html